We own 28% of chk1. 100% of aurora + flt3 outside china 100% of tyk2 in cancer. Majority in autoimmune.
I believe it could be worth 50p in 2 years once p1 completes.
However on signing a licence before then 5p to 10p. If we get taken over in the next 3 months which I suspect is on the cards 20p is not unreasonable and at the lower end of similar deals at the moment in this space.
I have been with SAR since 2009, never sold on that massive spike in 2011, put it down to inexperience, just held. Have increased my holding in recent months and am just about to realise profit at long last. I am here to the very end, for me that would be a buy out by a large pharma. GLA with the same view as me.
Forgetting sentiment we are at a critical juncture pending nhs approval we will be on azn watchlist. I'm loading up here and angle due to their breakthroughs in liquid biopsy. Both have huge upside and are on major pharma radars.
Totally agree my fellow Lutonian, I am another long term invester of SAR. The BB is going crazy with rediculious speculations, ramping, deramping. There is so much positivity in this share, I say hold tight and wait because exciting times are very near. Thoth, Shat2 keep up the good work, GLA
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.